Chen Chao, Du Shiyu, Zhong Wu, Liu Kunguo, Qu Lihua, Chu Feiyi, Yang Jingjing, Han Xin
Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, School of Medicine, Hunan Normal University, Changsha, 410013, China.
Nano Converg. 2022 Nov 24;9(1):52. doi: 10.1186/s40580-022-00343-5.
Chemoresistance remains a huge challenge for effective treatment of non-small cell lung cancer (NSCLC). Previous studies have shown Chinese herbal extracts possess great potential in ameliorating tumor chemoresistance, however, the efficacy is clinically limited mainly because of the poor tumor-targeting and in vivo stability. The construction of nano-delivery systems for herbal extracts has been shown to improve drug targeting, enhance therapeutic efficacy and reduce toxic and side effects. In this study, a folic acid (FA)-modified nano-herb micelle was developed for codelivery of pristimerin (PRI) and paclitaxel (PTX) to enhance chemosensitivity of NSCLC, in which PRI could synergistically enhance PTX-induced growth inhibition of A549 cancer cell. PTX was firstly grafted with the FA-linked polyethylene glycol (PEG) and then encapsulated with PRI to construct the PRI@FA-PEG-PTX (P@FPP) nano-micelles (NMs), which exhibited improved tumor-targeting and in vivo stability. This active-targeting P@FPP NMs displayed excellent tumor-targeting characteristics without obvious toxicity. Moreover, inhibition of tumor growth and metastasis induced by P@FPP NMs were significantly enhanced compared with the combined effects of the two drugs (PRI in combination of PTX), which associated with epithelial mesenchymal transition inhibition to some extent. Overall, this active-targeting NMs provides a versatile nano-herb strategy for improving tumor-targeting of Chinese herbal extracts, which may help in the promotion of enhancing chemosensitivity of NSCLC in clinical applications.
化疗耐药仍然是有效治疗非小细胞肺癌(NSCLC)的巨大挑战。先前的研究表明,中草药提取物在改善肿瘤化疗耐药性方面具有巨大潜力,然而,其疗效在临床上受到限制,主要原因是肿瘤靶向性差和体内稳定性差。已证明构建用于中草药提取物的纳米递送系统可改善药物靶向性、增强治疗效果并减少毒副作用。在本研究中,开发了一种叶酸(FA)修饰的纳米草药胶束,用于共递送鸦胆子素(PRI)和紫杉醇(PTX)以增强NSCLC的化疗敏感性,其中PRI可协同增强PTX诱导的A549癌细胞生长抑制作用。首先将PTX与FA连接的聚乙二醇(PEG)接枝,然后用PRI包封以构建PRI@FA-PEG-PTX(P@FPP)纳米胶束(NMs),其表现出改善的肿瘤靶向性和体内稳定性。这种主动靶向的P@FPP NMs表现出优异的肿瘤靶向特性且无明显毒性。此外,与两种药物(PRI与PTX联合)的联合作用相比,P@FPP NMs诱导的肿瘤生长和转移抑制作用显著增强,这在一定程度上与上皮间质转化抑制有关。总体而言,这种主动靶向的NMs为改善中草药提取物的肿瘤靶向性提供了一种通用的纳米草药策略,这可能有助于在临床应用中提高NSCLC的化疗敏感性。